Floatz logo

Sucralose

Short Bowel Syndrome

Northwestern UniversityPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Short Bowel Syndrome cohort.

Asset / SponsorPhaseRating
LACTULOSE
Northwestern University
Phase 4BB
Genotropin
Northwestern University
Phase 4BB
MANNITOL
Northwestern University
Phase 4B
Glepaglutide
Zealand Pharma
Phase 3B
Loperamide
Odense University Hospital
Phase 3B

View all 10 →

Same molecule, other indications

Sucralose is also rated in:

Healthy VolunteersDormant
CCC
Indicative ·
53 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
48 / 100
View asset →
obesity disorderDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →